Solid Malignancies Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Solid Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Hematologic MalignanciesSolid Malignancies
Immunome, Inc.117 enrolled12 locationsNCT06823167
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

Advanced Solid MalignanciesAdvanced Solid Tumor Malignancies
West China Hospital12 enrolled1 locationNCT06927297
Recruiting
Phase 1Phase 2

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies
Biocity Biopharmaceutics Co., Ltd.180 enrolled1 locationNCT07368478
Recruiting
Phase 1

A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

Solid Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.138 enrolled15 locationsNCT06725381
Recruiting
Phase 1Phase 2

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

Solid Malignancies
Carrick Therapeutics Limited50 enrolled6 locationsNCT06600789
Recruiting
Phase 1

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

Solid Malignancies
Taizhou Mabtech Pharmaceutical Co.,Ltd55 enrolled1 locationNCT06933069
Recruiting
Phase 1Phase 2

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies
Georgiamune Inc111 enrolled11 locationsNCT06028074
Recruiting
Not Applicable

PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors

CancerSolid Malignancies
Affiliated Hospital of Jiangnan University30 enrolled1 locationNCT06684028
Recruiting
Phase 1Phase 2

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Advanced Solid TumorAdvanced Solid Malignancies
Zhuhai Yufan Biotechnologies Co., Ltd267 enrolled5 locationsNCT05315167
Recruiting

Predictors of Immune Related Adverse Events from the use of the Immunotherapy in Patients with Cancer

Solid Malignancies where patients are receiving immune checkpoint inhibitors - either alone or in combination with other anti-cancer agents
Western Sydney University120 enrolled2 locationsACTRN12621001146886